Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.

Literature DB >> 26224766

Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.

Abstract

The in vitro hollow fiber system model has been qualified by the European Medicines Agency as a methodology for use in support of selection and development of antituberculosis regimens. More data are expected to be generated in the future to further characterize its value.

Entities: Disease

Keywords: EMA; PK/PD; in vitro models; qualification; tuberculosis

Mesh：

Substances：
Antitubercular Agents

Year: 2015 PMID： 26224766 DOI： 10.1093/cid/civ484

Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079

Keyword Cloud
Cited

15 in total

1. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Authors: Devyani Deshpande; Jotam G Pasipanodya; Stellah G Mpagama; Shashikant Srivastava; Paula Bendet; Thearith Koeuth; Pooi S Lee; Scott K Heysell; Tawanda Gumbo
Journal: Clin Infect Dis Date: 2018-11-28 Impact factor: 9.079

2. Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.

Authors: I Portillo-Calderón; M Ortiz-Padilla; B de Gregorio-Iaria; V Merino-Bohorquez; J Blázquez; J Rodríguez-Baño; J M Rodríguez-Martínez; A Pascual; F Docobo-Pérez
Journal: Antimicrob Agents Chemother Date: 2021-03-08 Impact factor: 5.191

3. Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

Authors: Sander P van Rijn; Marlanka A Zuur; Richard Anthony; Bob Wilffert; Richard van Altena; Onno W Akkerman; Wiel C M de Lange; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191

4. Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?

Authors: G L Drusano; Brandon Duncanson; C A Scanga; S Kim; S Schmidt; M N Neely; W M Yamada; Michael Vicchiarelli; C A Peloquin; Arnold Louie
Journal: Antimicrob Agents Chemother Date: 2020-11-17 Impact factor: 5.191

5. The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.

Authors: G L Drusano; Sarah Kim; Mohammed Almoslem; Stephan Schmidt; D Z D'Argenio; Jenny Myrick; Brandon Duncanson; Jocelyn Nole; David Brown; C A Peloquin; Michael Neely; Walter Yamada; Arnold Louie
Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191

Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.

1. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

2. Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.

3. Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

4. Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?

5. The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.

6. Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

7. Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

8. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

Review 9. Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.

10. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.